This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

"What excites us most about this discovery is that it indicates plants may control their microbiomes, in part, by regulating gene expression in microbes using cross-kingdom RNA interference, also ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion ...

Functional genomics can help deconvolute the link between genotype and phenotype in disease, revealing new drug targets and ...

[28] RNA interference (RNAi) is a naturally occurring biological pathway in which small, double-stranded RNA molecules suppress gene expression in an exquisitely sequence-specific manner Exogenous ...

The FDA has accepted for review the New Drug Application for plozasiran for the treatment for familial chylomicronemia syndrome.

An FDA approval later this year for Arrowhead’s plozasiran in FCS would put it in direct competition with Ionis’ Tryngolza.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to discuss its financial results for the fiscal ...

With its International Headquarters in Zug, Switzerland, Alnylam has become a key part of the Swiss biotech environment.

Benitec has a market cap of $250mn, $67.8mn in cash, and a cash runway of over 10 quarters, but faces risks due to its small ...